CRISPR Therapeutics (NASDAQ: CRSP) saw a surge in its stock a few years ago when its gene editing therapy, Casgevy, was approved for blood disorders. Despite recent declines, the technology is seen as a game-changer for treating illnesses by “fixing” underlying problems with one treatment.

CRISPR Therapeutics and Vertex Pharmaceuticals obtained approval for Casgevy for sickle cell disease and beta thalassemia, but revenue generation has been slow due to the complex process involved. Vertex projects over $100 million in revenue in 2025, with profit sharing between the companies slowing down significant gains.

The company’s pipeline includes more candidates based on CRISPR gene editing technology, which may take time to generate revenue. Stock performance has been affected by high expectations post-approval, leading some to view CRISPR Therapeutics as yesterday’s news despite its potential as a player in the biotech industry.

Read more at Yahoo Finance: Is CRISPR Therapeutics Stock Yesterday’s News?